Handelen FibroGen, Inc - FGEN CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.28 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 17.63 |
| Open* | 17.47 |
| 1-Jaarlijkse Verandering* | 70.61% |
| Dagelijks bereik* | 15.59 - 17.48 |
| 52 wekelijks bereik | 8.67-25.69 |
| Weekgemiddelde volume (10 dagen) | 1.11M |
| Gemiddeld volume (3 maanden) | 19.31M |
| Marktkapitalisatie | 1.74B |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 97.58M |
| Omzet | 116.07M |
| EPS | -3.27 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.79 |
| Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 9, 2023 | 16.82 | -0.25 | -1.46% | 17.07 | 17.63 | 15.55 |
| Jun 8, 2023 | 17.63 | 1.31 | 8.03% | 16.32 | 17.85 | 16.28 |
| Jun 7, 2023 | 17.02 | -0.97 | -5.39% | 17.99 | 18.42 | 16.35 |
| Jun 6, 2023 | 18.54 | -0.46 | -2.42% | 19.00 | 19.14 | 18.53 |
| Jun 5, 2023 | 19.05 | 1.83 | 10.63% | 17.22 | 19.43 | 17.22 |
| Jun 2, 2023 | 17.79 | -0.94 | -5.02% | 18.73 | 19.05 | 17.34 |
| Jun 1, 2023 | 17.18 | 0.22 | 1.30% | 16.96 | 17.59 | 16.70 |
| May 31, 2023 | 17.16 | 0.15 | 0.88% | 17.01 | 17.61 | 16.72 |
| May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
FibroGen, Inc Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Monday, June 12, 2023 | ||
| Tijd (UTC) (UTC) 18:20 | Land US
| Evenement FibroGen Inc at Goldman Sachs Healthcare Conference FibroGen Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Friday, June 16, 2023 | ||
| Tijd (UTC) (UTC) 15:00 | Land US
| Evenement FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Inkomsten | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Totale bedrijfskosten | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Onderzoek & Ontwikkeling | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Bedrijfsresultaat | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Netto inkomen voor belastingen | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Netto inkomen na belastingen | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Netto inkomen voor extra. Posten | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Netto inkomen | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Verwaterd Netto Inkomen | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Verwaterd Gewogen Gemiddelde Aandelen | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Verwaterde Genormaliseerde Winst per Aandeel | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Totale buitengewone posten | |||||
| Kosten van opbrengsten, totaal | 20.28 | 12.871 | 8.869 | 1.147 | |
| Brutowinst | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Inkomsten | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Kosten van opbrengsten, totaal | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Brutowinst | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Totale bedrijfskosten | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Onderzoek & Ontwikkeling | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Bedrijfsresultaat | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Netto inkomen voor belastingen | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Netto inkomen na belastingen | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Netto inkomen voor extra. Posten | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Netto inkomen | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Verwaterd Netto Inkomen | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Verwaterd Gewogen Gemiddelde Aandelen | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Geldmiddelen en kortetermijnbeleggingen | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Geldmiddelen & Equivalenten | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Korte Termijn Investeringen | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Totale Vorderingen, Netto | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Geldmiddelen en kortetermijnbeleggingen | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Geldmiddelen & Equivalenten | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Korte Termijn Investeringen | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Totale Vorderingen, Netto | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Geldmiddelen uit Operationele Activiteiten | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Geldmiddelen uit Operationele Activiteiten | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Niet-Geldelijke Posten | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Contant Betaalde Rente | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Veranderingen in het Operationeel Kapitaal | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Geldmiddelen uit Investeringsactiviteiten | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Kapitaaluitgaven | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Overige Cash Flow investeringsposten, Totaal | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Geldmiddelen uit Financieringsactiviteiten | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Financiering van Cash Flow Posten | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Uitgifte (Aflossing) van aandelen, netto | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Uitgifte (Aflossing) van Schulden, Netto | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Wisselkoerseffecten | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Nettowijziging in Geldmiddelen | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | HIGH |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | MED |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
FibroGen, Inc Company profile
Over FibroGen, Inc
FibroGen, Inc. is een biofarmaceutisch bedrijf. Het bedrijf houdt zich bezig met het ontdekken, ontwikkelen en commercialiseren van een pijplijn van eersteklas therapeutica. De Vennootschap past haar capaciteiten toe in hypoxia-inducible factor (HIF) biologie, 2-oxoglutaraat enzymologie, en bindweefselgroeifactor (CTGF) biologie om geneesmiddelen te ontwikkelen voor de behandeling van anemie, fibrotische aandoeningen en kanker. Roxadustat is een oraal in te nemen kleine molecule die de activiteit van HIF-prolylhydroxylase (HIF-PH) remt voor de behandeling van bloedarmoede veroorzaakt door chronische nieraandoeningen (CKD). De Vennootschap ontwikkelt Roxadustat ook voor anemie die geassocieerd wordt met myelodysplastische syndromen (MDS). Het bedrijf ontwikkelt Roxadustat ook voor de behandeling van chemotherapie-geïnduceerde anemie (CIA). Pamrevlumab, een anti-CTGF humaan monoklonaal antilichaam voor de behandeling van idiopathische longfibrose (IPF), lokaal gevorderde niet-resectabele pancreaskanker (LAPC) en Duchenne spierdystrofie (DMD).
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen